

Hello,

It is my understanding that spironolactone suspension has continued to be compounded by some pharmacies due to the lack of Medicaid coverage of the commercially available product Carospir. It seems this will no longer be possible given the hazardous drug handling precautions mandated by USP 800 (in addition to being in direct conflict with the Board of Pharmacy regulation against compounding commercially available products). Given these constraints, will Carospir now be eligible for coverage for our pediatric heart patients? I am working with peds cardiology to provide a suspension to a 23 month old.